Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Jones Hall, Yava L ^a   Kozik, Ariangela ^a,b   Nakatsu, Cindy ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S; TUMOR NECROSIS FACTOR; BACTERIAL DNA; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEROIDETES; BODY WEIGHT; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; DOWN REGULATION; FEMALE; FIRMICUTES; GENE AMPLIFICATION; GENOTYPE; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE NECROSIS; INTESTINE ULCER; MICROBIAL COMMUNITY; MICROBIOME; MOUSE; NONHUMAN; PHYLOGENY; POLYMERIZATION; PROTEIN FUNCTION; RECTUM HEMORRHAGE; SEQUENCE ANALYSIS; ANIMAL; BACTERIUM; CHEMICALLY INDUCED; CLASSIFICATION; COLITIS, ULCERATIVE; DISEASE MODEL; FECES; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY;

MUS;

ANIMALS; BACTERIA; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; FECES; FEMALE; HUMANS; MICE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925002919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119441     Document Type: Article

References (66)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317. doi: 10.1038/nature10209 PMID: 21677747
2. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008; 8: 458-466. doi: 10.1038/nri2340 PMID: 18500230
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. PMID: 17653185
4. Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009; 27: 455-464. doi: 10.1159/000235851 PMID: 19897960
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002, 347: 417-429. PMID: 12167685
6. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008; 105: 15064-15069. doi: 10.1073/pnas.0803124105 PMID: 18806221
7. Matsuo K, Ota H, Akamatsu T, Sugiyama A, Katsuyama T. Histochemistry of the surface mucous gel layer of the human colon. Gut. 1997; 40: 782-789. PMID: 9245933
8. Sheng YH, Hasnain SZ, Florin TH, McGuckin MA. Mucins in inflammatory bowel diseases and colorectal cancer. J Gastroenterol Hepatol. 2012; 27: 28-38. doi: 10.1111/j.1440-1746.2011.06909.x PMID: 21913981
9. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl. 2012; 1: 15-21.
10. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014; 14: 141-153. doi: 10.1038/nri3608 PMID: 24566914
11. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005, 65: 2253-2286. PMID: 16266194
12. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009; 15: 5784-5788. PMID: 19998498
13. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm. 2009; 2009: 297645. doi: 10.1155/2009/297645 PMID: 19503799
14. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014; 7: 6-19. doi: 10.1038/mi.2013.73 PMID: 24084775
15. Claesson MJ, Jeffery IB, Conde S, Power SE, O#x2019;Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012, 488: 178-184. doi: 10.1038/nature11319 PMID: 22797518
16. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011; 474: 327-336. doi: 10.1038/nature10213 PMID: 21677749
17. Li K, Bihan M, Yooseph S, Methe BA. Analyses of the microbial diversity across the human microbiome. PLoS ONE. 2012, 7: e32118. doi: 10.1371/journal.pone.0032118 PMID: 22719823
18. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014; 63: 1513-1521. doi: 10.1136/gutjnl-2014-306928 PMID: 24833634
19. Bushman FD, Lewis JD, Wu GD. Diet, the human gut microbiota, and IBD. Anaerobe. 2013; 30: 00052-00058.
20. Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013; 48: 315-321. doi: 10.1007/s00535-013-0777-2 PMID: 23475322
21. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol. 2013; 6: 53-68. doi: 10.1177/1756283X12454590 PMID: 23320050
22. Sha S, Xu B, Wang X, Zhang Y, Wang H, Kong X, et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis. 2013; 75: 245-251. doi: 10.1016/j.diagmicrobio.2012.11.022 PMID: 23276768
23. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012; 35: 327-334. doi: 10.1111/j.1365-2036.2011.04939.x PMID: 22150569
24. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014; 146: 1489-1499. doi: 10.1053/j.gastro.2014.02.009 PMID: 24560869
25. Papa E, Docktor M, Smillie C, Weber S, Preheim SP, Gevers D, et al.: Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS ONE. 2012; 7: e39242. doi: 10.1371/journal.pone.0039242 PMID: 22768065
26. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012; 13: R79. doi: 10.1186/gb-2012-13-9-r79 PMID: 23013615
27. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992; 339: 89-91. PMID: 1345871
28. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol. 1995; 46: 111-123. PMID: 8926619
29. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn#x2019;s disease. J Clin Immunol. 1996; 16: 144-150. PMID: 8734357
30. van Deventer SJ. Review article: Chemokine production by intestinal epithelial cells: a therapeutic target in inflammatory bowel disease? Aliment Pharmacol Ther. 1997; 3: 116-120. PMID: 9467986
31. Thukral C, Travassos WJ, Peppercorn MA. The Role of Antibiotics in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005; 8:223-228. PMID: 15913511
32. Feagan BG, Enns R, Fedorak RN, Panaccione R, Pare P, Steinhart AH, et al. Infliximab for the treatment of Crohn#x2019;s disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol. 2001; 8: 188-198. PMID: 11743591
33. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007; 56: 1125-1133. PMID: 17393394
34. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn#x2019;s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31. PMID: 14699483
35. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med. 2006; 100: 1291-1293. PMID: 16545951
36. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003; 167: 1279-1282. PMID: 12615627
37. Abreu C, Magro F, Santos-Antunes J, Pilao A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population. J Crohns Colitis. 2013; 10: 00108-00106.
38. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol. 2000, 19:51-62. PMID: 10723677
39. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002; 20: 495-549. PMID: 11861611
40. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996; 184: 1397-1411. PMID: 8879212
41. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2: 541-546. PMID: 17406617
42. Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T, et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol. 2003; 18: 560-569. PMID: 12702049
43. Liu ZZ, DeSantis TZ, Andersen GL, Knight R. Accurate taxonomy assignments from 16S rRNA sequences produced by highly parallel pyrosequencers. Nucleic Acids Res. 2008; 36: e120. doi: 10.1093/nar/gkn491 PMID: 18723574
44. Nossa CW, Oberdorf WE, Yang LY, Aas JA, Paster BJ, DeSantis TZ, et al. Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome. World J Gastroenterol. 2010; 16: 4135-4144. PMID: 20806429
45. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics. 2012; 13: 31. doi: 10.1186/1471-2105-13-31 PMID: 22333067
46. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Meth. 2010; 7: 335-336.
47. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012; 6: 610-618. doi: 10.1038/ismej.2011.139 PMID: 22134646
48. Hamady M, Lozupone C, Knight R. Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data. ISME J. 2010; 4: 17-27. doi: 10.1038/ismej.2009.97 PMID: 19710709
49. Anderson M. A new method for non-parametric multivariate analysis of variance. Austral Ecology 2001; 26: 32-46.
50. Anderson MJ. Distance-based tests for homogeneity of multivariate dispersions. Biometrics. 2006; 62: 245-253. PMID: 16542252
51. ter Braak CJF. Canonical correspondence analysis: A new eigenvector technique for multivariate direct gradient analysis. Ecology. 1986; 67: 1167-1179.
52. Tuomisto H. A diversity of beta diversities: straightening up a concept gone awry. Part 1. Defining beta diversity as a function of alpha and gamma diversity. Ecography. 2010; 33: 2-22.
53. Noti M, Corazza N, Mueller C, Berger B, Brunner T. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med. 2010; 207: 1057-1066. doi: 10.1084/jem.20090849 PMID: 20439544
54. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997; 27: 1743-1750. PMID: 9247586
55. Shen C, Hertogh Gd, Bullens DMA, Assche GV, Geboes K, Rutgeerts P, et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization? Inflamm Bowel Dis. 2007; 13: 308-316. PMID: 17206708
56. Fries W, Muja C, Crisafulli C, Costantino G, Longo G, Cuzzocrea S, et al. Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. Int J Med Sci. 2008; 5: 169-180. PMID: 18645606
57. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn#x2019;s disease by tumour necrosis factor alpha antibody treatment. Gut. 2004; 53: 1295-1302. PMID: 15306588
58. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest. 2011; 121: 1722-1732. doi: 10.1172/JCI42917 PMID: 21490394
59. Iizuka M, Konno S. Wound healing of intestinal epithelial cells. World J Gastroenterol. 2011; 17: 2161-2171. doi: 10.3748/wjg.v17.i17.2161 PMID: 21633524
60. Bel S, Elkis Y, Elifantz H, Koren O, Ben-Hamo R, Lerer-Goldshtein T, et al. Reprogrammed and transmissible intestinal microbiota confer diminished susceptibility to induced colitis in TMF-/- mice. Proc Natl Acad Sci U S A. 2014; 111: 4964-4969. doi: 10.1073/pnas.1319114111 PMID: 24639530
61. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2014; 8: 1403-1417. doi: 10.1038/ismej.2014.3 PMID: 24500617
62. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011; 5: 220-230. doi: 10.1038/ismej. 2010.118 PMID: 20686513
63. Presley LL, Wei B, Braun J, Borneman J. Bacteria associated with immunoregulatory cells in mice. Appl Environ Microbiol. 2010; 76: 936-941. doi: 10.1128/AEM.01561-09 PMID: 20008175
64. Bosshard PP, Zbinden R, Altwegg M. Turicibacter sanguinis gen. nov., sp. nov., a novel anaerobic, Gram-positive bacterium. Int J Syst Evol Microbiol. 2002; 52: 1263-1266. PMID: 12148638
65. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2014; 8: 1403-1417. doi: 10.1038/ismej.2014.3 PMID: 24500617
66. Sarowska J, Choroszy-Krol I, Regulska-Ilow B, Frej-Madrzak M, Jama-Kmiecik A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Adv Clin Exp Med. 2013; 22: 759-766. PMID: 24285463